Phase II Study of Cisplatin plus Cetuximab in Advanced, Recurrent, and Previously Treated Cancers of the Cervix and Evaluation of Epidermal Growth Factor Receptor Immunohistochemical Expression: A Gynecologic Oncology Group Study

BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of cetuximab (C225), an antibody that inhibits epidermal growth factor receptor (EGFR) activity, with cisplatin and to explore associations between EGFR protein expression with patient demographics or clinical outcome. MET...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Farley, John, Sill, Michael W., Birrer, Michael, Walker, Joan, Schilder, Russell J., Thigpen, J. Tate, Coleman, Robert L, Miller, Brigitte E., Rose, Peter G., Lankes, Heather A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2011
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3081894/
https://ncbi.nlm.nih.gov/pubmed/21329967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2011.01.030
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg